Zobrazeno 1 - 10
of 509
pro vyhledávání: '"Sabine C, Linn"'
Autor:
Joost G.E. Verbeek, Leyla Azarang, Luis E. Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In
Externí odkaz:
https://doaj.org/article/20428d92475a4fe8be71426416fab27c
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Autor:
Mark Opdam, Annelot G.J. van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M. Horlings, Erik van Werkhoven, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J. Rutgers, Renee X. de Menezes, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Sabine C. Linn, Marcel Soesan, Rianne M. Oosterkamp, Frank Jeurissen, Nir Weijl, Karin J. Beelen, Aart van Bochove, Gerty de Klerk, Suzan Vrijaldenhoven, Annette van der Velden, Hiltje de Graaf, Marielle Smeets, Jetske Meerum Terwogt, Jolanda Schrama, Philomeen Kuijer, Hanneke Wilmink, Ronald Hoekstra, Judith Kroep, Hans F.M. Pruijt, Leander van Gerven, Allert H. Vos, Frans Erdkamp, Willemien G. van Leeuwen-Breuk, Alexander de Graeff
Publikováno v:
iScience, Vol 27, Iss 8, Pp 110425- (2024)
Summary: The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can
Externí odkaz:
https://doaj.org/article/3dae747c44804a5fafa1281b33a3c21c
Autor:
Yuwei Wang, Gwen M. H. E. Dackus, Efraim H. Rosenberg, Sten Cornelissen, Leonora W. de Boo, Annegien Broeks, Wim Brugman, Terry W. S. Chan, Paul J. van Diest, Michael Hauptmann, Natalie D. ter Hoeve, Olga I. Isaeva, Vincent M. T. de Jong, Katarzyna Jóźwiak, Roelof J. C. Kluin, Marleen Kok, Esther Koop, Petra M. Nederlof, Mark Opdam, Philip C. Schouten, Sabine Siesling, Charlaine van Steenis, Adri C. Voogd, Willem Vreuls, Roberto F. Salgado, Sabine C. Linn, Marjanka K. Schmidt
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this population remains unclear. In addition, whether BRCA1-related bio
Externí odkaz:
https://doaj.org/article/ddff242b9c864f39864f3885aee7bad4
Autor:
Sonja Vliek, Florentine S. Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H. Lips, Lennart Mulder, Mutamba T. Kayembe, Claudette E. Loo, Nicola S. Russell, Marie-Jeanne T. F. D. Vrancken Peeters, Marjo J. Holtkamp, Margaret Schot, Joke W. Baars, Aafke H. Honkoop, Annelie J. E. Vulink, Alex L. T. Imholz, Suzan Vrijaldenhoven, Franchette W. P. J. van den Berkmortel, Jetske M. Meerum Terwogt, Jolanda G. Schrama, Philomeen Kuijer, Judith R. Kroep, Annemieke van der Padt-Pruijsten, Jelle Wesseling, Gabe S. Sonke, Kenneth G. A. Gilhuijs, Agnes Jager, Petra Nederlof, Sabine C. Linn
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-alt
Externí odkaz:
https://doaj.org/article/8df2c3c9b54e4fdaa94ca1a2ca82efc6
Autor:
Leonie Voorwerk, Joyce Sanders, Milou S. Keusters, Sara Balduzzi, Sten Cornelissen, Maxime Duijst, Esther H. Lips, Gabe S. Sonke, Sabine C. Linn, Hugo M. Horlings, Marleen Kok
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for E
Externí odkaz:
https://doaj.org/article/bf1f76273f634aa69a34a1e2029a1773
Autor:
Joost G. E. Verbeek, Vincent M. T. de Jong, Hanna M. Wijnja, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiven
Externí odkaz:
https://doaj.org/article/5fd17baec0f84cdea280548a6e6950e0
Autor:
Vivianne C.G. Tjan-Heijnen, Senna W.M. Lammers, Sandra M.E. Geurts, Ingeborg J.H. Vriens, Astrid C.P. Swinkels, Carolien H. Smorenburg, Maurice J.C. van der Sangen, Judith R. Kroep, Hiltje de Graaf, Aafke H. Honkoop, Frans L.G. Erdkamp, Wilfred K. de Roos, Sabine C. Linn, Alexander L.T. Imholz
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101901- (2023)
Summary: Background: The DATA study evaluated the use of two different durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2–3 years of tamoxifen. We hereby present the follow-up analysis, w
Externí odkaz:
https://doaj.org/article/5623c66d14bc4b84bad476914391d5ba
Autor:
Stacey E. P. Joosten, Marius Wellenstein, Rutger Koornstra, Annelot van Rossum, Joyce Sanders, Vincent van der Noort, Maria C. Ferrandez, Rolf Harkes, Ingrid A. M. Mandjes, Hilde Rosing, Alwin Huitema, Jos H. Beijnen, Jelle Wesseling, Paul J. van Diest, Hugo M. Horlings, Sabine C. Linn, Wilbert Zwart
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response. Immunohistochemistry (IHC)-based Ki67 o
Externí odkaz:
https://doaj.org/article/d14fa82c2abe4ab4ace6a27f694de818
Autor:
Sandra Tavares, Nalan Liv, Milena Pasolli, Mark Opdam, Max A.K. Rätze, Manuel Saornil, Lilian M. Sluimer, Rutger C.C. Hengeveld, Robert van Es, Erik van Werkhoven, Harmjan Vos, Holger Rehmann, Boudewijn M.T. Burgering, Hendrika M. Oosterkamp, Susanne M.A. Lens, Judith Klumperman, Sabine C. Linn, Patrick W.B. Derksen
Publikováno v:
Cell Reports, Vol 39, Iss 1, Pp 110584- (2022)
Summary: Elevated expression of non-receptor tyrosine kinase FER is an independent prognosticator that correlates with poor survival of high-grade and basal/triple-negative breast cancer (TNBC) patients. Here, we show that high FER levels are also as
Externí odkaz:
https://doaj.org/article/9434a26e702a448687ec52764f334902
Autor:
Esther H. Lips, Anne Benard-Slagter, Mark Opdam, Caroline E. Scheerman, Jelle Wesseling, Frans B. L. Hogervorst, Sabine C. Linn, Suvi Savola, Petra M. Nederlof
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break inducing chemotherapy
Externí odkaz:
https://doaj.org/article/80a0d3ee97954d7c860270878592b294